Institution
New York Blood Center
Nonprofit•New York, New York, United States•
About: New York Blood Center is a nonprofit organization based out in New York, New York, United States. It is known for research contribution in the topics: Antigen & Antibody. The organization has 1875 authors who have published 3324 publications receiving 151660 citations.
Topics: Antigen, Antibody, Population, Virus, Men who have sex with men
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In this article, the optimal immunogen dosage and immunization interval were optimized using a recombinant MERS-coronavirus (MERS-CoV) RBD fragment fused with Fc (S377-588-Fc) to evaluate the protective efficacy of RBD against MERS infection in human dipeptidyl peptidase 4 transgenic (hDPP4-Tg) mice.
Abstract: Middle East respiratory syndrome (MERS) continues to raise worldwide concerns due to its pandemic potential. Increased MERS cases and no licensed MERS vaccines highlight the need to develop safe and effective vaccines against MERS. We have previously demonstrated that a receptor-binding domain (RBD) fragment containing residues 377–588 of MERS-coronavirus (MERS-CoV) spike protein is a critical neutralizing domain and an important vaccine target. Nevertheless, its optimal immunogen dosage and immunization interval, key factors for human-used vaccines that induce protective immunity, have never been investigated. In this study, we optimized these criteria using a recombinant MERS-CoV RBD protein fused with Fc (S377–588-Fc) and utilized the optimal immunization schedule to evaluate the protective efficacy of RBD against MERS-CoV infection in human dipeptidyl peptidase 4 transgenic (hDPP4-Tg) mice. Compared with one dose and 2 doses at 1-, 2-, and 3-week intervals, a regimen of 2 doses of this protein...
52 citations
••
TL;DR: Non-occupational post-exposure prophylaxis (nPEP) use is an HIV prevention strategy that has been recommended by the CDC to prevent HIV infection after a high risk sexual exposure since 1997, and willingness to use nPEP after high risk sex was associated with lower odds of highrisk sex.
Abstract: Non-occupational post-exposure prophylaxis (nPEP) use is an HIV prevention strategy that has been recommended by the CDC to prevent HIV infection after a high risk sexual exposure since 1997. In a behavioral intervention trial of 4,295 MSM we assessed perceptions and use of nPEP over 4 years in six cities across the United States. Overall, 1.9% of MSM reported use of nPEP prior to enrollment, and 6.3% at least once during the trial. Awareness of nPEP was reported by 47.5%, with higher awareness in two sites with funded nPEP programs. Three seroconversions occurred in the 384 visits where nPEP courses were reported, with no effect of nPEP on risk of HIV acquisition in this cohort (hazard ratio = 0.91, 95% confidence interval [0.29, 2.86]). NPEP users were a riskier group: increased odds of nPEP use were observed in association with multiple partners and unprotected receptive and insertive anal sex with HIV infected partners and partners with unknown HIV status. NPEP use was also associated with use of illicit drugs (injection drugs, crack cocaine, hallucinogens, and amphetamines). Importantly, willingness to use nPEP after high risk sex was associated with lower odds of high risk sex. After an episode of nPEP use, nPEP users remained more likely to report high risk sex than those in this cohort who had not previously used nPEP. However, within the subset of people who had previously reported high risk sex, previous nPEP use was not associated with higher odds of high risk sex, thus allaying fears that availability of nPEP would lead to an increase in high risk sex.
52 citations
••
TL;DR: Comparative studies on the red cells of 12 newborn infants suggest that the same sequence of I antigen development occurs in them all, but different infants vary in the amount of I development that they have achieved at the time of birth.
Abstract: . The I blood group antigen has two main components named IFetal (IF) and IDeveloped (Id). The IF component is present on all human red cells including those of icord and iadult persons, and also on Rhesus monkey red cells. The ID component develops slowly on the red cells before birth and to a greater extent in the 18 months after birth. Inhibition studies with human milk show that strongly-inhibitable anti-I sera are of the anti-ID variety, but only a minority of such sera are inhibitable. Comparative studies on the red cells of 12 newborn infants suggest that the same sequence of I antigen development occurs in them all, but different infants vary in the amount of I development that they have achieved at the time of birth. I antigen variants affect mainly the ID component, and it is this part of the antigen that may be weakened on the red cells of people with leukemia.
52 citations
••
TL;DR: Plerixafor was well tolerated but did not achieve consistent CD34+ cell mobilization in this cohort of patients, most of whom were being actively treated with hydroxyurea and only one was chronically transfused.
Abstract: Gene therapy for sickle cell disease is limited by the yield of hematopoietic progenitor cells that can be harvested for transduction or gene editing. We therefore performed a phase I dose-escalation study of the hematopoietic progenitor cell mobilizing agent plerixafor to evaluate the efficacy and safety of standard dosing on peripheral blood CD34+ cell mobilization. Of 15 patients enrolled to date, only one was chronically transfused and ten were on hydroxyurea. Of eight patients who achieved a CD34+ cell concentration >30 cells/μL, six were on hydroxyurea. There was no clear dose response to increasing plerixafor dosage. There was a low rate of serious adverse events; two patients developed vaso-occlusive crises, at the doses of 80 μg/kg and 240 μg/kg. Hydroxyurea may have contributed to the limited CD34+ mobilization by affecting baseline peripheral blood CD34 counts, which correlated strongly with peak peripheral blood CD34 counts. Plerixafor administration did not induce significant increases in the fraction of activated neutrophils, monocytes, or platelets. However, increased neutrophils positive for activated β2 integrin and Mac-1 were associated with serious adverse events. In summary, plerixafor was well tolerated but did not achieve consistent CD34+ cell mobilization in this cohort of patients, most of whom were being actively treated with hydroxyurea and only one was chronically transfused. The study will continue with escalation of the dose of plerixafor and modification of hydroxyurea administration. Clinicaltrials.gov identifier: NCT02193191.
52 citations
••
TL;DR: The fused portions of gp41 NHR are fused to the T4 fibritin trimerization domain, Foldon, thus constructing novel NHR trimers, designated N36Fd or N28Fd, which could be expressed in Escherichia coli cells and exhibited SDS-resistant trimeric coiled-coil conformation with improved α-helicity compared with the corresponding N-peptides.
52 citations
Authors
Showing all 1877 results
Name | H-index | Papers | Citations |
---|---|---|---|
Robert H. Purcell | 139 | 666 | 70366 |
Kenneth H. Mayer | 115 | 1351 | 64698 |
Arne Holmgren | 113 | 407 | 44645 |
Woodring E. Wright | 109 | 356 | 53087 |
Paul D. Cleary | 107 | 386 | 44313 |
Søren Nielsen | 105 | 806 | 45995 |
Margaret A. Chesney | 101 | 326 | 33509 |
Narla Mohandas | 100 | 448 | 30892 |
Alessandro M. Vannucchi | 94 | 715 | 35482 |
Ross L. Coppel | 93 | 539 | 29001 |
Harvey J. Alter | 92 | 277 | 36032 |
Jules L. Dienstag | 91 | 301 | 36721 |
Andrew X. Zhu | 89 | 489 | 41539 |
James B. Bussel | 86 | 558 | 30011 |
Shibo Jiang | 84 | 549 | 28414 |